| 02-01-2012 04:59 AM CET - Health & Medicine |
|
Translational Imaging to improve probability of success in drug development
Press release from: SMi Group
(openPR) - Join SMi at their 8th annual Imaging in Cancer Drug Development conference that promises to be interactive and informative. With an increasing verity of imaging modalities available and each of them offering benefits at different stages and in different ways, there is a great deal of benefit that can be gained from their implementation.
You will hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the development process, how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardize imaging result from multi centre clinical trials
Benefits of attending
Examine the benefits of different imaging modalities and she how they can be best applied in your investigations
Review case studies on the use of imaging in multi centre clinical trials and how different teams have overcome the challenges associated with them.
Determine how upcoming EU regulations will affect the way oncology trials use of imaging will be conducted
Gain knowledge of using imaging techniques, when used, can reduce the long term cost of drug development
Communicate with industry experts on the current applications of imaging in all stages of drug design
Participate at the interactive workshop on how molecular imaging can reduce the cost of drug development
Make sure not to miss this opportunity to attend and hear from our expert speakers, including:
• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research
TO BOOK
Please visit: www.smi-online.co.uk/cancer-imaging50.asp
Alternatively contact: Ninica Hussain 0207 827 6115 or nhussain@smi-online.co.uk
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
SMi Group Ltd
2nd Floor South, Harling House 47-51 Great Suffolk Street,
London, SE1 0BS
You will hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the development process, how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardize imaging result from multi centre clinical trials
Benefits of attending
Examine the benefits of different imaging modalities and she how they can be best applied in your investigations
Review case studies on the use of imaging in multi centre clinical trials and how different teams have overcome the challenges associated with them.
Determine how upcoming EU regulations will affect the way oncology trials use of imaging will be conducted
Gain knowledge of using imaging techniques, when used, can reduce the long term cost of drug development
Communicate with industry experts on the current applications of imaging in all stages of drug design
Participate at the interactive workshop on how molecular imaging can reduce the cost of drug development
Make sure not to miss this opportunity to attend and hear from our expert speakers, including:
• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research
TO BOOK
Please visit: www.smi-online.co.uk/cancer-imaging50.asp
Alternatively contact: Ninica Hussain 0207 827 6115 or nhussain@smi-online.co.uk
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
SMi Group Ltd
2nd Floor South, Harling House 47-51 Great Suffolk Street,
London, SE1 0BS
News-ID: 209106
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
SMi Group
Comments about openPR
OpenPR ist the nicest and most clearly laid out PR platform I have seen to this day. The press releases are displayed very nicely and clearly and without any unnecessary frills.
The updates are fast and the finished release looks appealing and is clearly legible.
Even with 16 years of experience one discovers new things from time to time.
Congratulations!
Gabriele Ketterl,Director Marketing & PR, Menads
The updates are fast and the finished release looks appealing and is clearly legible.
Even with 16 years of experience one discovers new things from time to time.
Congratulations!
Gabriele Ketterl,Director Marketing & PR, Menads

